Rifampin Injection shortage
Current 4 presentations · 3 manufacturers · first FDA posting 2021-02-17 · last update 2026-10-15
Manufacturers: Fresenius Kabi USA, LLC, Mylan Institutional, a Viatris Company, Sanofi-Aventis U.S. LLC
Stated reasons (per FDA): Demand increase for the drug; Discontinuation of the manufacture of the drug; Other
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Rifampin, Injection, 600 mg (NDC 63323-351-20) | Fresenius Kabi USA, LLC | Current Limited Availability |
Other | Check wholesalers for inventory | Posted 02/17/2021 Updated 10/15/2026 |
| Rifampin, Injection, 600 mg (NDC 67457-445-60) | Mylan Institutional, a Viatris Company | Current Unavailable |
Demand increase for the drug | Estimated recovery: Q4 2026 | Posted 02/17/2021 Updated 10/05/2026 |
| Rifadin, Injection, 600 mg (NDC 0068-0597-01) | Sanofi-Aventis U.S. LLC | Current Unavailable |
Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug | Posted 02/17/2021 Updated 09/18/2026 |
| Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01) | Sanofi-Aventis U.S. LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 04/20/2026 Updated 04/20/2026 Discontinued 04/20/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)